Co-Authors
This is a "connection" page, showing publications co-authored by DEBORAH A KUBAN and KAREN HOFFMAN.
Connection Strength
5.504
-
Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. J Clin Oncol. 2018 10 10; 36(29):2943-2949.
Score: 0.649
-
Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial. Am J Clin Oncol. 2018 Jun; 41(6):558-567.
Score: 0.640
-
Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1074-84.
Score: 0.480
-
Lymph node-positive prostate cancer: the benefit of local therapy. Oncology (Williston Park). 2013 Jul; 27(7):655, 660-1.
Score: 0.455
-
In Reply to Akhtar et al. Pract Radiat Oncol. 2024 Sep-Oct; 14(5):466-467.
Score: 0.247
-
Implementation and Efficacy of a Large-Scale Radiation Oncology Case-Based Peer-Review Quality Program across a Multinational Cancer Network. Pract Radiat Oncol. 2024 May-Jun; 14(3):e173-e179.
Score: 0.236
-
Patients' Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer. MDM Policy Pract. 2022 Jul-Dec; 7(2):23814683221137752.
Score: 0.218
-
Reply to Multidisciplinary clinics: A possible means to help to eliminate racial disparities in prostate cancer. Cancer. 2020 06 15; 126(12):2939-2940.
Score: 0.181
-
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2020 02 01; 126(3):506-514.
Score: 0.177
-
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548.
Score: 0.153
-
Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):249-258.
Score: 0.151
-
The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. Am J Clin Oncol. 2016 08; 39(4):368-73.
Score: 0.141
-
Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med. 2014 Sep; 174(9):1450-9.
Score: 0.123
-
Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw. 2014 Jul; 12(7):993-8.
Score: 0.122
-
Current clinical presentation and treatment of localized prostate cancer in the United States. J Urol. 2014 Dec; 192(6):1650-6.
Score: 0.122
-
Local recurrence map to guide target volume delineation after radical prostatectomy. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):e239-46.
Score: 0.120
-
Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer. 2013 Sep 15; 119(18):3265-71.
Score: 0.114
-
Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer. 2013 Aug 01; 119(15):2771-7.
Score: 0.112
-
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):e39-46.
Score: 0.109
-
Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):693-9.
Score: 0.107
-
Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer. 2012 Jul; 48(11):1664-71.
Score: 0.103
-
Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J. 2012 Jan-Feb; 18(1):1-8.
Score: 0.103
-
Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol. 2011 Jan; 185(1):116-20.
Score: 0.095
-
Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center. Clin Transl Radiat Oncol. 2024 Sep; 48:100822.
Score: 0.061
-
Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy. Brachytherapy. 2020 Sep - Oct; 19(5):574-583.
Score: 0.046
-
Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):982-985.
Score: 0.046
-
Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Pract Radiat Oncol. 2020 Jul - Aug; 10(4):282-292.
Score: 0.046
-
Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Netw Open. 2020 03 02; 3(3):e201255.
Score: 0.045
-
Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU Int. 2019 11; 124(5):811-819.
Score: 0.043
-
Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):790-797.
Score: 0.042
-
Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):374-382.
Score: 0.038
-
Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality-of-Life Trial. Int J Part Ther. 2016; 3(1):27-36.
Score: 0.035
-
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
Score: 0.033
-
Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Dec 01; 87(5):946-53.
Score: 0.029
-
Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy. 2014 Mar-Apr; 13(2):157-62.
Score: 0.029
-
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy. 2013 May-Jun; 12(3):204-9.
Score: 0.026
-
Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):e7-e13.
Score: 0.026